摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.5,91.21,25]-hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-dodecaene-34,36-diol | 185675-92-7

中文名称
——
中文别名
——
英文名称
15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.5,91.21,25]-hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-dodecaene-34,36-diol
英文别名
15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.(5,9)1.(13,17)1.(21,25)]-hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29.31.1(36)-dodecaene-34,36-diol;15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.(5,9)1.(13,17)1.(21,25)]hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-dodecaene-34,36-diol;24RBPyBC;7,23-dimethyl-3,11,19,27,33,35-hexazapentacyclo[27.3.1.15,9.113,17.121,25]hexatriaconta-1(33),5,7,9(36),13(35),14,16,21(34),22,24,29,31-dodecaene-34,36-diol
15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.<sup>5,9</sup>1.<sup>21,25</sup>]-hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-dodecaene-34,36-diol化学式
CAS
185675-92-7
化学式
C32H38N6O2
mdl
——
分子量
538.693
InChiKey
FWSXILLPHLXROP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    40
  • 可旋转键数:
    0
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    114
  • 氢给体数:
    6
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Antisense Agents Combining Strongly Bound Base-Modified Oligonucleotide and Artificial Nuclease
    申请人:Karelson Mati
    公开号:US20070259830A1
    公开(公告)日:2007-11-08
    The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy.
    本发明提供了具有螯合基团和寡核苷酸序列的化合物,其中寡核苷酸包括一个或多个修饰的核碱基,例如羟基核碱基。所述化合物适用于反义疗法。螯合基团可以与属离子形成络合物。这些化合物是核酸的高效翻译抑制剂,并且对目标核酸具有增强的结合亲和力。本发明还包括使用这些组合物作为反义疗法的组合物和方法。
  • Interactions between Divalent Metal Ions and an Octacoordinate Macrocyclic Ligand
    作者:Haiyang He、Arthur E. Martell、Ramunas J. Motekaitis、Joseph H. Reibenspies
    DOI:10.1021/ic9911264
    日期:2000.4.1
    sites of the dinucleating macrocycle (N3O-), and the other is that the metal ions occupy salen-like sites of the macrocycle (N3O(2)2-). In the 2:1 systems (2:1 molar ratio of metal ion to ligand), the mononuclear species predominate in acidic solutions while the dinuclear species predominate in basic solutions, except for the case of copper. The protonated mononuclear complex [H2LZn](NO3)(2).5H2O forms
    双核六氮杂二大环配体15,31-二甲基-3,11,19,27,33,35-六氮杂五环[27.3.1.1。(5,9)1.(13,17)1。(21,25)] hexaconaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-十二碳烯34,36-二醇(H2L)与二价属离子Cu2 +,Cd2 +,Mn2 +和Zn2 +形成许多质子化,中性和/或羟基单核,同核和杂核复合物,并受属离子和配体化学计量控制作为溶液的pH值。确定了它们的稳定常数和物种分布与p [H]的关系。pH电位研究表明,双核络合物是通过单核螯合物形成的,其中观察到两种配位模式。一种是属离子正好通过成核大环化合物(N3O-)的一半配位位点络合,另一种是属离子占据了大环化合物(N3O(2)2-)的Salen样位点。在2:1系统(属离子与配体的摩尔比为2:1)中,单核物
  • Dinuclear lanthanum complex catalyzes the hydrolysis of a phosphate diester with unprecedented speed
    作者:Paul E. Jurek、Arthur E. Martell
    DOI:10.1039/a900860h
    日期:——
    The dihydroxo dilanthanum macrocyclic complex hydrolyzes bis(p-nitrophenyl) hydrogen phosphate (BNP) with a remarkably high rate constant and a unique third-order dependence on the concentration of the dinuclear complex.
    二羟基二大环配合物可解双(对硝基苯基)磷酸氢盐 (BNP),具有非常高的速率常数和对双核配合物浓度的独特三阶依赖性。
  • STRONGLY BOUND BASE-MODIFIED OLIGONUCLEOTIDES
    申请人:KARELSON MATI
    公开号:US20120171279A1
    公开(公告)日:2012-07-05
    The present invention provides compounds having a chelating moiety and an oligonucleotide sequence wherein the oligonucleotide includes one or more modified nucleobases, such as hydroxynucleobases. The disclosed compounds are suitable for antisense therapy. The chelating moiety can be complexed to an ion of a lanthanide metal. These compounds are efficient translation inhibitors of nucleic acids and have increased binding affinity for target nucleic acids. The invention also includes compositions and methods of using these compositions as antisense therapy.
    本发明提供了具有螯合基团和寡核苷酸序列的化合物,其中寡核苷酸包括一个或多个修饰的核碱基,例如羟基核碱基。所述化合物适用于反义治疗。螯合基团可以与属离子形成络合物。这些化合物是核酸的有效翻译抑制剂,并具有增加的靶标核酸结合亲和力。本发明还包括这些化合物的组合物和使用这些组合物作为反义治疗的方法。
  • Macrocyclic dinuclear copper(II) complex with a novel chloride bridged zigzag chain
    作者:Tongbu Lu、Shi Chen、Zongwan Mao、A.E. Martell、Liangnian Ji
    DOI:10.1016/s1387-7003(03)00195-3
    日期:2003.8
    A macrocyclic dinuclear copper complex Cu2LCl(ClO4).H2O, where L = 15,31-dimethyl-3,11,19,27,33,35-hexaazapentacyclo[27.3.1.1.(5;9)1(13;17)1.(21,25)]-hexatriaconta-5,7,9(33),13,15,17(34),21,23,25(35),29,31,1(36)-dodecaene-34,36-diol, has been synthesized and characterized by single-crystal X-ray diffraction. In the complex, each Cu(II) ion is coordinated with three macrocyclic nitrogen atoms and one phenolate oxygen anion. The dinuclear copper complexes are linked by the bridged Cl- to form a novel zigzag chain with a folded chair conformation. (C) 2003 Elsevier Science B.V. All rights reserved.
查看更多